Evaluation of pemetrexed (Alimta, LY231514) as second-line chemotherapy in persistent or recurrent carcinoma of the cervix: The CERVIX 1 study of the MITO (Multicentre Italian Trials in Ovarian Cancer and Gynecologic Malignancies) Group

Annals of Oncology

Volumn 21, Issue 1, 2009, Pages 61-66

  Lorusso, D ^a   Ferrandina, G ^b   Pignata, S ^c   Ludovisi, M ^b   Vigano R ^d   Scalone, S ^e   Scollo, P ^f   Breda, E ^g   Pietragalla, A ^a   Scambia, G ^a  

^a CATHOLIC UNIVERSITY   (Italy)

^b CATHOLIC UNIVERSITY   (Italy)

^c National Cancer Institute   (Italy)

^d SAN RAFFAELE HOSPITAL   (Italy)

^e CENTRO DI RIFERIMENTO ONCOLOGICO   (Italy)

^f CANNIZZARO HOSPITAL   (Italy)

^g FATEBENEFRATELLI HOSPITAL   (Italy)

Author keywords

Chemotherapy; Pemetrexed; Recurrent cervical cancer

Indexed keywords

CYANOCOBALAMIN; DEXAMETHASONE; FOLIC ACID; PEMETREXED;

ADULT; AGED; ALKALINE PHOSPHATASE BLOOD LEVEL; ALOPECIA; AMINOTRANSFERASE BLOOD LEVEL; ANEMIA; ANOREXIA; ARTICLE; ASTHENIA; BLOOD TOXICITY; CANCER GRADING; CANCER RECURRENCE; CANCER STAGING; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; DIARRHEA; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG ERUPTION; DRUG HYPERSENSITIVITY; DRUG TOLERABILITY; FEMALE; HISTOPATHOLOGY; HUMAN; LEUKOPENIA; LIVER TOXICITY; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUROTOXICITY; NEUTROPENIA; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; SIDE EFFECT; THROMBOCYTOPENIA; TREATMENT RESPONSE; UTERINE CERVIX CARCINOMA; VOMITING;

EID: 77749303127     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdp266     Document Type: Article

References (51)

1. Ferlay J, Bray F, Piscini P et al. Globocan 2000. Cancer Incidence, Mortality and Prevalence Worldwide. Lyon, France: IARC 2001 Version 1.0.
2. Green JA, De Barros Lopes A. Optimizing treatment for cervical cancer: the value of chemoradiation. Am J Cancer 2004; 3: 215-227.
3. Neoadjuvant Chemotherapy for Cervical Cancer Meta-analysis Collaboration. Neoadjuvant chemotherapy for locally advanced cervical cancer: a systematic review and meta-analysis of individual patient data from 21 randomised trials. Eur J Cancer 2003; 39: 2470-2486.
4. Thigpen T, Shingleton H, Homesley H et al. Cis-platinum in treatment of advanced or recurrent squamous cell carcinoma of the cervix: a phase II study of the Gynecologic Oncology Group. Cancer 1981; 48: 899-903.
5. Sutton GP, Blessing JA, Adcock L et al. Phase II study of ifosfamide and mesna in patients with previously-treated carcinoma of the cervix. A Gynecologic Oncology Group study. Invest New Drugs 1989; 7: 341-343.
6. Sutton GP, Blessing JA, DiSaia PJ, McGuire WP. Phase II study of ifosfamide and mesna in nonsquamous carcinoma of the cervix: a Gynecologic Oncology Group study. Gynecol Oncol 1993; 49: 48-50.
7. Bloss JD, Blessing JA, Behrens BC et al. Randomized trial of cisplatin and ifosfamide with or without bleomycin in squamous carcinoma of the cervix: a Gynecologic Oncology Group study. J Clin Oncol 2002; 20: 1832-1837.
8. Look KY, Blessing JA, Gallup DG, Lentz SS. A phase II trial of 5-fluorouracil and high-dose leucovorin in patients with recurrent squamous cell carcinoma of the cervix: a Gynecologic Oncology Group study. Am J Clin Oncol 1996; 19: 439-441.
9. Rose PG, Blessing JA, Van Le L, Waggoner S. Prolonged oral etoposide in recurrent or advanced squamous cell carcinoma of the cervix: a Gynecologic Oncology Group study. Gynecol Oncol 1998; 70: 263-266.
10. Schilder RJ, Blessing JA, Morgan M et al. Evaluation of gemcitabine in patients with squamous cell carcinoma of the cervix: a phase II study of the Gynecologic Oncology Group. Gynecol Oncol 2000; 76: 204-207.
11. Bookman MA, Blessing JA, Hanjani P et al. Topotecan in squamous cell carcinoma of the cervix: a phase II study of the Gynecologic Oncology Group. Gynecol Oncol 2000; 77: 446-449.
12. Curtin JP, Blessing JA, Webster KD et al. Paclitaxel, an active agent in nonsquamous carcinomas of the uterine cervix: a Gynecologic Oncology Group study. J Clin Oncol 2001; 19: 1275-1278.
13. Fracasso PM, Blessing JA, Wolf J et al. Phase II evaluation of oxaliplatin in previously treated squamous cell carcinoma of the cervix: a Gynecologic Oncology Group study. Gynecol Oncol 2003; 90: 177-180.
14. Muggia FM, Blessing JA, Method M et al. Evaluation of vinorelbine in persistent or recurrent squamous cell carcinoma of the cervix: a Gynecologic Oncology Group study. Gynecol Oncol 2004; 92: 639-643.
15. Bigler LR, Tate Thigpen J, Blessing JA et al. Evaluation of tamoxifen in persistent or recurrent nonsquamous cell carcinoma of the cervix: a Gynecologic Oncology Group study. Int J Gynecol Cancer 2004; 14: 871-874.
16. Schilder RJ, Blessing J, Cohn DE. Evaluation of gemcitabine in previously treated patients with non-squamous cell carcinoma of the cervix: a phase II study of the Gynecologic Oncology Group. Gynecol Oncol 2005; 96: 103-107.
17. Muggia FM, Blessing JA, Waggoner S et al. Evaluation of vinorelbine in persistent or recurrent nonsquamous carcinoma of the cervix: a Gynecologic Oncology Group study. Gynecol Oncol 2005; 96: 108-111.
18. Brewer CA, Blessing JA, Nagourney RA et al. Cisplatin plus gemcitabine in previously treated squamous cell carcinoma of the cervix: a phase II study of the Gynecologic Oncology Group. Gynecol Oncol 2006; 100: 385-388.
19. Rose PG, Blessing JA, Lele S, Abulafia O. Evaluation of pegylated liposomal doxorubicin (Doxil) as second-line chemotherapy of squamous cell carcinoma of the cervix: a phase II study of the Gynecologic Oncology Group. Gynecol Oncol 2006; 102: 210-213.
20. Bonomi P, Blessing J, Ball H et al. A phase II evaluation of cisplatin and 5-fluorouracil in patients with advanced squamous cell carcinoma of the cervix: a Gynecologic Oncology Group study. Gynecol Oncol 1989; 34: 357-359.
21. Sutton GP, Blessing JA, McGuire WP et al. Phase II trial of ifosfamide and mesna in patients with advanced or recurrent squamous carcinoma of the cervix who had never received chemotherapy: a Gynecologic Oncology Group study. Am J Obstet Gynecol 1993; 168: 805-807.
22. Thigpen T, Blessing JA, Gallup DG et al. Phase II trial of mitomycin-C in squamous cell carcinoma of the uterine cervix: a Gynecologic Oncology Group study. Gynecol Oncol 1995; 57: 376-379.
23. McGuire WP, Blessing JA, Moore D et al. Paclitaxel has moderate activity in squamous cervix cancer. A Gynecologic Oncology Group study. J Clin Oncol 1996; 14: 792-795.
24. Lincoln S, Blessing JA, McGehee R, Lentz SS. Phase II trial of piroxantrone in advanced squamous cell carcinoma of the cervix: a Gynecological Oncology Group study. Am J Clin Oncol 1997; 20: 84-85.
25. Look KY, Blessing JA, Levenback C et al. A phase II trial of CPT-11 in recurrent squamous carcinoma of the cervix: a Gynecologic Oncology Group study. Gynecol Oncol 1998; 70: 334-338.
26. Muderspach LI, Blessing JA, Levenback C, Moore JL Jr. A phase II study of topotecan in patients with squamous cell carcinoma of the cervix: a Gynecologic Oncology Group study. Gynecol Oncol 2001; 81: 213-215.
27. Rose PG, Blessing JA, Gershenson DM, McGehee R. Paclitaxel and cisplatin as first-line therapy in recurrent or advanced squamous cell carcinoma of the cervix: a Gynecologic Oncology Group study. J Clin Oncol 1999; 17: 2676-2680.
28. Morris M, Blessing JA, Monk BJ et al. Phase II study of cisplatin and vinorelbine in squamous cell carcinoma of the cervix: a Gynecologic Oncology Group study. J Clin Oncol 2004; 22: 3340-3344.
29. Muggia FM, Blessing JA, McGehee R, Monk BJ. Cisplatin and irinotecan in squamous cell carcinoma of the cervix: a phase II study of the Gynecologic Oncology Group. Gynecol Oncol 2004; 94: 483-487.
30. Garcia AA, Blessing JA, Darcy KM et al. Phase II clinical trial of capecitabine in the treatment of advanced, persistent or recurrent squamous cell carcinoma of the cervix with translational research: a Gynecologic Oncology Group study. Gynecol Oncol 2007; 104: 572-579.
31. Monk BJ, Huang HQ, Cella D, Long HJ III. Quality of life outcomes from a randomized phase III trial of cisplatin with or without topotecan in advanced carcinoma of the cervix: a Gynecologic Oncology Group study. J Clin Oncol 2005; 23: 4617-4625.
32. Long HJ III, Bundy BN, Grendys EC Jr et al. Randomized phase III trial of cisplatin with or without topotecan in carcinoma of the uterine cervix: a Gynecologic Oncology Group study. J Clin Oncol 2005; 23: 4626-4633.
33. Long HJ III, Monk BJ, Huang HQ et al. Clinical results and quality of life analysis for the MVAC combination (methotrexate, vinblastine, doxorubicin, and cisplatin) in carcinoma of the uterine cervix: a Gynecologic Oncology Group study. Gynecol Oncol 2006; 100: 537-543.
34. Moore DH, Blessing JA, McQuellon RP et al. Phase III study of cisplatin with or without paclitaxel in stage IVB, recurrent, or persistent squamous cell carcinoma of the cervix: a Gynecologic Oncology Group study. J Clin Oncol 2004; 22: 3113-3119.
35. Thodtmann R, Depenbrock H, Dumez H et al. Clinical and pharmacokinetic phase I study of multitargeted antifolate (LY231514) in combination with cisplatin. J Clin Oncol 1999; 17: 3009-3016.
36. Bunn P, Paoletti P, Niyikiza C et al. Vitamin B12 and folate reduce toxicity of Alimta™ (pemetrexed disodium, LY231514, MTA), a novel antifolate/antimetabolite. Proc Am Soc Clin Oncol 37th annual meeting program/proceedings, American Society of Clinical Oncology. 2001; 20: 76a (Abstr 300).
37. Niyikiza C, Baker SD, Seitz DE et al. Homocysteine and methylmalonic acid: markers to predict and avoid toxicity from pemetrexed therapy. Mol Cancer Ther 2002; 1: 545-552.
38. Nakagawa K, Kudoh S, Matsui K et al. A phase I study of pemetrexed (LY231514) supplemented with folate and vitamin B12 in Japanese patients with solid tumours. Br J Cancer 2006; 95: 677-682.
39. Takimoto CH, Hammond-Thelin LA, Latz JE et al. Phase I and pharmacokinetic study of pemetrexed with high-dose folic acid supplementation or multivitamin supplementation in patients with locally advanced or metastatic cancer. Clin Cancer Res 2007; 13: 2675-2683.
40. Malempati S, Nicholson HS, Reid JM et al. Phase I trial and pharmacokinetic study of pemetrexed in children with refractory solid tumors: the Children's Oncology Group. J Clin Oncol 2007; 25: 1505-1511.
41. Goedhals L, van Wiyk AL, Smith BL, Fourie SJ. Pemetrexed (Alimta, LY231514) demonstrates clinical activity in chemonaive patients with cervical cancer in a phase II single-agent trial. Int J Gynecol Cancer 2006; 16: 1172-1178.
42. Therasse P, Arbuck SG, Eisenhauer EA et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000; 92: 205-216.
43. Chen TT, Ng TH. Optimal flexible designs in phase II clinical trials. Stat Med 1998; 17: 2301-2312.
44. Monk BJ, McMeekin DS, Cohn DE et al. A randomized phase III trial of four cisplatin (CIS) containing doublet combinations in stage IVB, recurrent or persistent cervical carcinoma: a Gynecologic Oncology Group (GOG) study. J Clin Oncol 2008; 26 (Suppl): Abstr LBA5504.
45. Manegold C, Gatzemeier U, von Pawel J et al. Front-line treatment of advanced non-small-cell lung cancer with MTA (LY231514, pemetrexed disodium, ALIMTA) and cisplatin: a multicenter phase II trial. Ann Oncol 2000; 11: 435-440.
46. Shepherd FA, Dancey J, Arnold A et al. Phase II study of pemetrexed disodium, a multitargeted antifolate, and cisplatin as first-line therapy in patients with advanced nonsmall cell lung carcinoma: a study of the National Cancer Institute of Canada Clinical Trials Group. Cancer 2001; 92: 595-600.
47. Hanna N, Shepherd FA, Fossella FV et al. Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy. J Clin Oncol 2004; 22: 1589-1597.
48. Miller DS, Blessing JA, Bodurka DC et al. Evaluation of pemetrexed (Alimta, LY231514) as second line chemotherapy in persistent or recurrent carcinoma of the cervix: a phase II study of the Gynecologic Oncology Group. Gynecol Oncol 2008; 110: 65-70.
49. Vogelzang NJ, Rusthoven JJ, Symanowski J et al. Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol 2003; 21: 2636-2644.
50. Socinski MA, Weissman C, Hart LL et al. Randomized phase II trial of pemetrexed combined with either cisplatin or carboplatin in untreated extensive-stage small-cell lung cancer. J Clin Oncol 2006; 24: 4840-4847.
51. Janne PA, Wozniak AJ, Belani CP et al. Open-label study of pemetrexed alone or in combination with cisplatin for the treatment of patients with peritoneal mesothelioma: outcomes of an expanded access program. Clin Lung Cancer 2005; 7: 40-46.